Deborah Thomas

2.1k citations

19 papers · 1.3k indexed · h-index 13

Impact in

Hematology top 1%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
Genetics top 2%
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Hematology 10
- Chronic Myeloid Leukemia Treatments 9
Genetics 7
- Chronic Lymphocytic Leukemia Research 6

Co-authors: Jörge E. Cortes (12 shared papers)Hagop M. Kantarjian (11 shared papers)Susan O’Brien (10 shared papers)Farhad Ravandi (8 shared papers)Guillermo Garcia‐Manero (5 shared papers)William G. Wierda (5 shared papers)Stefan Faderl (6 shared papers)Alessandra Ferrajoli (4 shared papers)
Journals: Blood (6 papers)Cancer (4 papers)ACS Chemical Neuroscience (1 paper)British Journal of Haematology (1 paper)Journal of Clinical Oncology (1 paper)
Partner nations: United States Peru Slovakia

In The Last Decade

Deborah Thomas

19 papers receiving 1.3k citations

Peers

Countries citing papers authored by Deborah Thomas

Since Specialization

Citations

This map shows the geographic impact of Deborah Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Thomas more than expected).

Fields of papers citing papers by Deborah Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Thomas. The network helps show where Deborah Thomas may publish in the future.

Co-authors

The 25 scholars most cited alongside Deborah Thomas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Deborah Thomas Line = papers co-authored together Deborah Thomas links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work
1	First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia Blood ·Farhad Ravandi, Susan O’Brien, Deborah Thomas, Stefan Faderl, Dan Jones, Rebecca Garris, Samuel Dara, Jeffrey L. Jorgensen, Partow Kebriaei, Richard E. Champlin, Gautam Borthakur, Jan A. Burger, Alessandra Ferrajoli, Guillermo Garcia‐Manero, William G. Wierda, Jörge E. Cortes, Hagop M. Kantarjian	2010	244
2	Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype Blood ·Nitin Jain, Audrey Lamb, Susan O’Brien, Farhad Ravandi, Marina Konopleva, Elias Jabbour, Zhuang Zuo, Jeffrey L. Jorgensen, Pei Lin, Sherry Pierce, Deborah Thomas, Michael Rytting, Gautam Borthakur, Tapan M. Kadia, Jörge E. Cortes, Hagop M. Kantarjian, Joseph D. Khoury	2016	218
3	Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia Cancer ·Farhad Ravandi, Susan O’Brien, Jörge E. Cortes, Deborah Thomas, Rebecca Garris, Stefan Faderl, Jan A. Burger, Michael Rytting, Alessandra Ferrajoli, William G. Wierda, Srđan Verstovšek, Richard E. Champlin, Partow Kebriaei, Deborah McCue, Xuelin Huang, Elias Jabbour, Guillermo Garcia‐Manero, Zeev Estrov, Hagop M. Kantarjian	2015	156
4	Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome–positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses Blood ·Hagop M. Kantarjian, Jörge E. Cortes, Susan O’Brien, Francis J. Giles, Guillermo Garcia‐Manero, Stefan Faderl, Deborah Thomas, Sima Jeha, Mary Beth Rios, Laurie Letvak, Kathy Bochinski, Ralph B. Arlinghaus, Moshe Talpaz	2002	125
5	Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome Blood ·Jörge E. Cortes, Patricia Ault, Charles Koller, Deborah Thomas, Alessandra Ferrajoli, William G. Wierda, Mary Beth Rios, Laurie Letvak, Elizabeth S. Kaled, Hagop M. Kantarjian	2003	115
6	Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy Cancer ·Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Farhad Ravandi, Susan O’Brien, Deborah Thomas, Gabriela Vidal‐Senmache, William G. Wierda, Steven M. Kornblau, Jörge E. Cortes	2009	110
7	Outcome of adults with acute lymphocytic leukemia after second salvage therapy Cancer ·Susan O’Brien, Deborah Thomas, Farhad Ravandi, Stefan Faderl, Jörge E. Cortes, Gautum Borthakur, Sherry Pierce, Guillermo Garcia‐Manero, Hagop M. Kantarjian	2008	110
8	Kinase domain point mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia emerge after therapy with BCR‐ABL kinase inhibitors Cancer ·Dan Jones, Deborah Thomas, C. Cameron Yin, Susan O’Brien, Jörge E. Cortes, Elias Jabbour, Megan Breeden, Francis J. Giles, Weiqiang Zhao, Hagop M. Kantarjian	2008	96
9	Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome British Journal of Haematology ·Maha El-Zimaity, Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Francis J. Giles, Guillermo Garcia‐Manero, Srđan Verstovšek, Deborah Thomas, Alessandra Ferrajoli, Kimberly Hayes, B. Nebiyou Bekele, Xian Zhou, Mary Beth Rios, Armand B. Glassman, Jörge E. Cortes	2004	74
10	BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome–positive leukemias Blood ·Dan Jones, Rajyalakshmi Luthra, Jörge E. Cortes, Deborah Thomas, Susan O’Brien, Carlos E. Bueso‐Ramos, Seema Hai, Farhad Ravandi, M. Lima, Hagop M. Kantarjian, Jeffrey L. Jorgensen	2008	28
11	Targeting MYC with modular synthetic transcriptional repressors derived from bHLH DNA-binding domains Nature Biotechnology ·Thomas E. Speltz, Z. Qiao, Colin Swenson, Xianghang Shangguan, John S. Coukos, Christopher Lee, Deborah Thomas, Jesse Santana, Sean W. Fanning, Geoffrey L. Greene, Raymond E. Moellering	2022	19
12	Solvatochromic and pH-Sensitive Fluorescent Membrane Probes for Imaging of Live Cells ACS Chemical Neuroscience ·Deborah Thomas, Vicente Rubio, Vijaya Iragavarapu, Esther A. Guzmán, Oliver B. Pelletier, Shahriar Alamgir, Qi Zhang, Maciej Stawikowski	2021	13
13	Tackling Undruggable Targets with Designer Peptidomimetics and Synthetic Biologics Chemical Reviews ·Colin Swenson, Gunasheil Mandava, Deborah Thomas, Raymond E. Moellering	2024	13
14	Study of cytosine arabinoside (NSC-63878) synchronization plus vincristine (NSC-67574), prednisone (NSC-10023), and L-asparaginase (NSC-109229) for remission induction in advanced acute leukemia in children. PubMed ·Sutow Ww, Deborah Thomas, Steuber Cp, J Pullen, Tribhawan S. Vats, Bryan Jh, Morgan Sk	1976	6
15	Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Blood ·Farhad Ravandi, Deborah Thomas, Hagop Kantarjian, Stefan Faderl, Charles Koller, Samuel Dara, Rebecca Garris, Partow Kebriaei, Gautam Borthakur, William G. Wierda, Jan A. Burger, Jörge E. Cortes, Susan O’Brien	2008	5
16	Phase II Study of Nelarabine With Hyper-CVAD in Patients With Previously Untreated T cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL) Clinical Lymphoma Myeloma & Leukemia ·Preetesh Jain, Hagop M. Kantarjian, Deborah Thomas, Farhad Ravandi, Tapan M. Kadia, Jan A. Burger, Gautam Borthakur, Jörge E. Cortes, Naval Daver, Elias Jabbour, Charles Koller, Marina Konopleva, Naveen Pemmaraju, Mary Ann Kelly, Rebecca Garris, Susan O’Brien, Stefan Faderl	2013	4
17	Direct inhibition of tumor hypoxia response with synthetic transcriptional repressors Nature Chemical Biology ·Z. Qiao, Long C. Nguyen, Dongbo Yang, Christopher Dann, Deborah Thomas, Madeline Henn, Andrea Valdespino, Colin Swenson, Scott A. Oakes, Marsha Rich Rosner, Raymond E. Moellering	2024	3
18	Imatinib mesylate for the treatment of locally advanced and/or metastatic pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Journal of Clinical Oncology ·Philippe A. Cassier, Silvia Stacchiotti, Hans Gelderblom, Deborah Thomas, W. van der Graaf, Beatrice Seddon, Danielle Julien, Amy J. Wagner, Jean‐Yves Blay	2010	3
19	Measuring Membrane Lipid Turnover with the pH-sensitive Fluorescent Lipid Analog ND6 Journal of Visualized Experiments ·Shahriar Alamgir, Oliver B. Pelletier, Deborah Thomas, Vicente Rubio, Maciej Stawikowski, Qi Zhang	2021	1

About Deborah Thomas

Deborah Thomas is a scholar working on Hematology, Genetics, Rheumatology, Public Health, Environmental and Occupational Health and Endocrinology, having authored 19 papers that have together received 1.3k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (9 papers), Acute Lymphoblastic Leukemia research (9 papers), Chronic Lymphocytic Leukemia Research (6 papers), Eosinophilic Disorders and Syndromes (5 papers), Childhood Cancer Survivors' Quality of Life (3 papers), Lymphoma Diagnosis and Treatment (2 papers), Protein Degradation and Inhibitors (2 papers) and Lipid Membrane Structure and Behavior (2 papers). The work is most often cited by research in Hematology (997 citations), Genetics (453 citations), Public Health, Environmental and Occupational Health (760 citations), Rheumatology (373 citations) and Oncology (288 citations). Deborah Thomas has collaborated with scholars based in United States, Peru and Slovakia. Frequent co-authors include Jörge E. Cortes, Hagop M. Kantarjian, Susan O’Brien, Farhad Ravandi, Guillermo Garcia‐Manero, William G. Wierda, Stefan Faderl, Alessandra Ferrajoli, Elias Jabbour and Jeffrey L. Jorgensen. Their work appears in journals such as Blood, Cancer, ACS Chemical Neuroscience, British Journal of Haematology and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact